

Cover Story
Conversation with The Cancer Letter
On Dec. 3, the faculty and staff members at the OHSU Knight Cancer Institute received an email from Brian J. Druker, the institution’s star scientist, former director, and current CEO, informing them that he would be stepping down from his executive role.
By Yiqing Wang
In Brief


Clinical Roundup
Drugs & Targets


NCI Trials


NCI Trials for December 2024
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- As daraxonrasib hits the clinic, Frank McCormick says RAS is bigger than pancreatic cancer
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Cancer leaders play “musical chairs” as executive jobs fill at top cancer centers
Lee replaces Pisters at MD Anderson, Tuveson moves to Duke, and Mitchell is named director at University of Florida - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - mRNA vaccine for melanoma is hailed as a turning point in medicine
The data from Moderna and Merck’s trial have yet to be presented
















